Femasys 8/10/2023 Earnings Report

Femasys EPS Results

• Actual EPS: -$0.22
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Femasys Revenue Results

• Actual Revenue: $0.32 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Femasys Announcement Details

• Date: 8/10/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Femasys (NASDAQ:FEMY), Inc. is a medical device company dedicated to the design, development and commercialization of minimally invasive diagnostic and therapeutic products for women’s reproductive health. Headquartered in Irvine, California, the company is listed on the NASDAQ under the ticker FEMY and focuses on single‐use catheter technologies that enhance procedure accuracy and patient comfort in fertility care.

Its flagship offerings include the FemVue™ catheter system for non‐radiation fallopian tube patency assessment and the FEMME™ embryo transfer catheter, both engineered with proprietary designs and radiopaque markers. These devices address key challenges in assisted reproductive technology by streamlining workflows, reducing patient discomfort and improving clinical outcomes in infertility clinics and hospitals.

Founded in 2012, Femasys serves markets across North America, Europe, Asia-Pacific and select emerging regions. The company has secured CE Mark approval in Europe and is actively pursuing regulatory clearances in the United States and China. Femasys leverages a combination of direct sales and distributor partnerships to expand its global footprint in the rapidly growing fertility device market.

Under the guidance of an experienced executive team, Femasys is advancing a pipeline of next‐generation catheter systems for enhanced uterine and tubal imaging. The company’s board of directors brings deep expertise in healthcare innovation, regulatory strategy and commercial expansion, positioning Femasys to broaden its product portfolio and scale operations worldwide.